Details

Autor(en) / Beteiligte

• Dotan, Arad
• Shoenfeld, Yehuda,

Titel

Autoimmunity, COVID-19, post-COVID-19 syndrome and COVID-19 vaccination

Ist Teil von

• Future of autoimmunity research ; : Volume 1

Ort / Verlag

London, United Kingdom ; : Elsevier, AP/Academic Press, An imprint of Elsevier,

Erscheinungsjahr

2023

Link zum Volltext

• Elsevier Books AutoHoldings

Beschreibungen/Notizen

• Includes bibliographical references and index.
• Front Cover -- AUTOIMMUNITY, COVID-19, POST-COVID19 SYNDROME AND COVID-19 VACCINATION -- FUTURE OF AUTOIMMUNITY RESEARCH : AUTOIMMUNITY, COVID-19, POST-COVID19 SYNDROME AND COVID-19 VACCINATION -- Copyright -- Contents -- List of contributors -- About the editors -- Foreword -- Preface -- 1 - Setting a context for autoantibodies, autoimmunity, and autoimmune diseases associated with SARS-CoV2 -- Introduction -- "Causes" of autoimmune diseases: a "mosaic" of genetic, environmental, and hormonal factors -- Historical context -- Controls and comparators -- Phenomenology is not pathology -- Time and timing is of the essence -- Temporarily does not equal causality -- Nobel 2021 PIEZO touch and temperature: COVID-19 myopathy -- Summary -- References -- 2 - The mosaic of autoimmunity and autoinflammation and SARS-CoV-2 as an environmental factor -- The mosaic of autoimmunity and autoinflammation -- SARS-CoV-2 and COVID-19 -- SARS-CoV-2 and biological mechanisms of virulence -- SARS-CoV-2 and COVID-19 as a further cobble of the mosaic of autoimmunity -- SARS-CoV-2/COVID-19 and its impact on autoimmune/autoinflammatory disorders -- Alopecia areata and telogen effluvium -- Amyloidosis -- Ankylosing spondylitis -- Antiphospholipid syndrome, catastrophic antiphospholipid syndrome, and HELLP syndrome -- Atopic dermatitis -- Autoimmune myopathies (myositis, dermatomyositis, and polymyositis) -- Autoimmune ocular diseases -- Autoimmune reproductive diseases -- Autoimmune thyroiditis, including Hashimoto's thyroiditis and Graves' disease -- Behçet's disease -- Celiac disease -- Demyelinating syndromes -- Autoimmune hemolytic anemia -- Immune thrombocytopenia -- Inflammatory arthritis/reactive arthritis -- Inflammatory bowel diseases -- Lichen planus, lichen planopilaris, and lichen sclerosus -- Miller-Fisher syndrome -- Multiple sclerosis.
• Myasthenia gravis and other autoimmune neuromuscular junction disorders -- Autoimmune myocarditis -- Pemphigus vulgaris and other autoimmune blistering diseases -- Polymyalgia rheumatica -- Postural orthostatic tachycardia syndrome -- Primary biliary cholangitis, primary sclerosing cholangitis, and other autoimmune cholangiopathies -- Psoriasis -- Psoriatic arthritis -- Rheumatoid arthritis -- Sarcoidosis -- Sjögren's syndrome -- Systemic lupus erythematosus -- Systemic sclerosis and scleroderma -- Type 1 diabetes -- Vasculitis -- Vitiligo -- Conclusions and future prospects -- References -- 3 - Innate immune responses in COVID-19 -- Introduction -- Innate immune responses to COVID-19: cells of the innate immune system -- Innate immune responses to COVID-19: NETosis and neutrophils -- Innate immune responses to COVID-19: inflammasome -- Canonical inflammasomes in COVID-19 -- Noncanonical inflammasomes and COVID-19 -- Innate immune responses to COVID-19: TLRs -- Innate immune responses to COVID-19: cytokines -- Innate immune responses to COVID-19: the human leukocyte antigen genotype -- Innate immune responses to COVID-19: autophagy -- Innate immune responses to COVID-19: the complement system -- Mechanisms of complement activation during the SARS-CoV-2 infection -- Mechanisms of complement pathogenicity in severe forms of COVID-19 -- Targeting complement for the treatment of COVID-19 -- Innate immune responses to COVID-19: protecting or aggravating factors, biomarkers of severity -- C-reactive protein (CRP) -- Procalcitonin (PCT) -- Liver transaminases and albumin -- Cardiac biomarkers -- Coagulation markers -- Innate immune responses to COVID-19: role of microbiota -- Innate immune responses to COVID-19: therapeutic developments -- IL-6 -- GM-CSF -- IL-1 and IL-1R -- Interferons (IFNs) -- JAKs -- Inflammasomes (sensors) -- Gasdermins.
• Inflammatory caspases and pan-caspase inhibition -- General comments and outlook -- Acknowledgments -- References -- 4 - The role of T cell immunity in COVID-19 -- Introduction -- Human corona virus -- Preformed memory -- T cells in the early infection -- The cytokine environment -- Lymphopenia -- Disease severity and T cells -- Dynamics of T cells in COVID-19 -- T cell functionality -- TCR signature in COVID-19 -- Conclusion -- References -- 5 - Laboratory characteristics of cytokine storm syndrome in COVID-19 infection -- Cytokine storm or cytokine release syndrome: definition and features -- Clinical examples of cytokine storm syndrome -- Prognostic value of cytokine measurement in COVID-19 -- Immunological patterns of secondary hemophagocytic lymphohistiocytosis, bacterial sepsis, and COVID-19 -- Cytokine storm syndrome score for disease prognosis -- Validation of cytokine storm syndrome score and its clinical relationship -- Conclusion remarks -- References -- 6 - COVID-19: the impact of the cytokine storm on the immune-neuroendocrine system -- Introduction -- COVID-19 infection, the cytokine storm and the immuno-neuroendocrine system -- The hypothalamic-pituitary-adrenal axis (HPA), COVID-19 infection, and cytokine storm -- The hypothalamic-pituitary-thyroid axis (HPT), COVID-19 infection, and cytokine storm -- The hypothalamic-pituitary-gonadal axis (HPG), COVID-19 infection, and cytokine storm -- The autonomic nervous system: sympathetic and parasympathetic, COVID-19 infection, and cytokine storm -- Central nervous system, cytokine storm, and COVID-19 -- Conclusions -- References -- 7 - Genetic predisposition to COVID-19 and post-COVID syndrome -- Introduction -- Genetic predisposing factors in COVID-19 -- The X chromosome-gender -- Expression of ACE2 and related proteins -- Expression of pro-inflammatory proteins and its receptors.
• HLA-genotypes -- ABO -- Predisposition to PCS -- Conclusions -- References -- 8 - Molecular mimicry and SARS-CoV-2 -- The concept of molecular mimicry and its relevance to autoimmunity -- Tools to study molecular mimicry -- Bioinformatic approaches investigating the role of SARS-CoV-2-related autoimmunity by molecular mimicry -- SARS-CoV-2, molecular mimicry, and Guillain-Barré syndrome -- SARS-CoV-2, molecular mimicry, and anti-phospholipid syndrome (APS) -- SARS-CoV-2 vaccination and autoimmunity -- SARS-CoV-2 and evidence of immunological cross-reactivity -- Conclusions -- References -- 9 - In silico study of molecular mimicry between SARS-CoV-2 and neutrophil extracellular traps composition in granu ... -- Introduction -- Materials and methods -- Blastp searches -- HLA binding predictions -- Proteins' features and network images -- Results and discussion -- Proteins associated with the highest number of different alleles -- This study versus HLA association studies of disease severity -- General features of the identified proteins -- SARS-CoV-2 and COVID-19-related features of the identified proteins -- Things-to-improve -- Conclusion -- Data availability -- Appendix -- References -- 10 - COVID-19 and the hyperferritinemic syndromes -- References -- 11 - SARS-CoV-2 and microbiome: pathology, implications and therapeutic options -- The microbiome, intestinal ecosystem, and immunoresistance: uniquely balanced -- Intestinal immune cells -- Signal pattern recognizing receptors -- Microbiome functions -- Gut microbiome dysbiosis and SARS-CoV-2 -- Dysbiosis and immune modulation of microbiota -- SARS-CoV-2 and microbiota -- Microbiome and therapeutic options in SARS-CoV-2 pandemic -- Probiotic foods: microbiome restoration and supplementation -- The role of probiotics in pathology correction.
• Modulation of the immune response through microbiota correction -- Postvaccination immunity modulation through microbiota correction -- Metabolic syndrome correction with probiotics -- Impact of COVID-19 on mental health and the role of microbiota -- Hyperreactive reactions and microbiota -- SARS-CoV-2 associated respiratory syndrome and microbiome -- Gastrointestinal pathology and COVID-19 -- The role of the microbiome in SARS-CoV-2 associated cytokine storm -- Metabiotics: novel treatment strategies -- Conclusion -- References -- 12 - Molecular and immunological evidence for SARS-CoV-2 being the autoimmune virus -- Introduction -- Criteria no. 1: identification of cross-reactive epitopes between SARS-CoV-2 and human tissue -- Criteria no. 2: reaction of animal and human monoclonal antibodies made against SARS-CoV-2 with human tissue antigens -- Criteria no. 3: reaction of antibody to human autoantigens with SARS-CoV-2 proteins -- Criteria no. 4: detection of autoantibodies against human tissue antigens in COVID-19 patients with different degrees of se ... -- Conclusions -- Acknowledgments -- References -- 13 - Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19 -- Hyperinflammation initiated by SARS-CoV-2 -- Autoantibodies in COVID-19 -- The break of peripheral immune tolerance in the context of SARS-CoV-2 -- Posttranslational modifications as triggers of neo-epitope formation and autoimmunity -- Proinflammatory autoantibodies in the context of SARS-CoV-2 -- PGRN-antibodies and immunogenic isoform pSer81PGRN in the context of SARS-CoV-2 -- IL-1-Ra-antibodies and the immunogenic pThr111 isoform of IL-1-Ra in the context of SARS-CoV-2 -- Remaining questions around proinflammatory autoantibodies related to SARS-CoV-2 -- Acknowledgment -- References -- 14 - What is common to MDA5 and COVID-19?.
• MDA5 receptor and anti-MDA5 autoantibody.
• Description based on print version record.